
NASDAQHealthcareMedical - Devices
最新資料
US$15.675
−US$0.165 · -1.04%
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
前收盤價
US$15.675
−US$0.165 · -1.04%
盤後
US$15.60
−US$0.075 · -0.48%
10月8日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
日內區間
目前US$15.675
52週區間
目前US$15.675
盤中時間採用ET。市場資料可能有所延遲。
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
日內區間
目前US$15.675
52週區間
目前US$15.675
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 10.15億 USD | 9.4億 USD | 7.48億 USD | 8.01億 USD | 7.03億 USD |
| 銷貨成本 | 4.84億 USD | 4.51億 USD | 3.8億 USD | 3.88億 USD | 3.27億 USD |
| 毛利 | 5.31億 USD | 4.9億 USD | 3.68億 USD | 4.13億 USD | 3.76億 USD |
| 研究與開發 | 1.75億 USD | 1.99億 USD | 2.48億 USD | 1.7億 USD | 9205.4萬 USD |
| 銷售、一般及管理費用 | 4.34億 USD | 3.9億 USD | 3.53億 USD | 3.36億 USD | 2.62億 USD |
| 營業費用 | 6.09億 USD | 5.89億 USD | 6.01億 USD | 5.06億 USD | 3.54億 USD |
| 利息收入 | 908.6萬 USD | 1799.3萬 USD | 2285.8萬 USD | 605.7萬 USD | 67.4萬 USD |
| 利息支出 | 790.7萬 USD | 741.5萬 USD | 988.2萬 USD | 620.8萬 USD | 604萬 USD |
| 折舊和攤銷 | 1766.6萬 USD | 1660.7萬 USD | 1571.5萬 USD | 1433萬 USD | 1384.5萬 USD |
| 營業利益 | −7812.2萬 USD | −9912.7萬 USD | −2.33億 USD | −9284.8萬 USD | 2265.3萬 USD |
| 淨利 | −2.05億 USD | −9602.5萬 USD | −2.23億 USD | −9459.4萬 USD | 1556.6萬 USD |
公司資料更新於 2026年10月9日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。